首页> 外文期刊>Journal of Clinical Microbiology >Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.
【24h】

Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.

机译:人血清中的人乳头瘤病毒18型E6和E7抗体:宫颈癌患者中抗E7患病率增加。

获取原文
           

摘要

Antibody-reactive regions on the human papillomavirus type 18 (HPV-18) E6 and E7 proteins were identified with rabbit polyclonal anti-fusion protein sera by screening of an fd phage expression library containing subgenomic HPV-18 DNA fragments and by testing of overlapping decapeptides representing the E6 and E7 open reading frames. Peptides comprising the delineated regions (designated E6/1 to E6/4 and E7/1) were synthesized and used in an enzyme-linked immunosorbent assay (ELISA) to detect anti-HPV-18 antibodies in human sera. A total of 232 human serum samples (identical numbers of cervical cancer patients and age-matched controls) collected in Tanzania were tested. Similar prevalences (between 0.8 and 4.3%) of antibodies recognizing the different E6 peptides were found in the sera from tumor patients and controls. With a synthetic 28-mer peptide (designated pepE701) comprising the E7/1 region, a significant difference was found: 10 of 116 tumor serum samples but 0 of 116 control serum samples showed a specific reaction (P less than 0.001). This observation confirms earlier results with HPV-16 E7 fusion proteins (I. Jochmus-Kudielka, A. Schneider, R. Braun, R. Kimmig, U. Koldovsky, K. E. Schneweis, K. Seedorf, and L. Gissmann, J. Natl. Cancer Inst. 81:1698-1704, 1989). A lower prevalence of anti-HPV-18 E7 antibodies was observed when 188 human serum samples collected in Germany from tumor patients and controls were tested (3 of 94 positive in the cancer group; 0 of 94 positive in the control group). The type specificity of anti-HPV-18 E7 antibodies was demonstrated when the HPV type found by Southern hybridization in the cervical cancer biopsies was compared with seroreactivity: 4 of 8 serum samples obtained from HPV-18 DNA-positive but 0 of 16 serum samples from HPV-18 DNA-negative tumor patients reacted in the HPV-18 E7 ELISA. In addition, HPV-18-positive sera failed to react in a peptide ELISA with the homologous HPV-16 E7 region (M. Müller, H. Gausepohl, G. de Martinoff, R. Frank, R. Brasseur, and L. Gissmann, J. Gen. Virol. 71:2709-2717, 1990) and vice versa.
机译:通过筛选包含亚基因组HPV-18 DNA片段的fd噬菌体表达文库并测试重叠的十肽,用兔多克隆抗融合蛋白血清鉴定了人乳头瘤病毒18型(HPV-18)E6和E7蛋白上的抗体反应区代表E6和E7开放阅读框。合成了包含划定区域(指定为E6 / 1至E6 / 4和E7 / 1)的肽,并将其用于酶联免疫吸附测定(ELISA)中以检测人血清中的抗HPV-18抗体。测试了在坦桑尼亚收集的232份人类血清样本(宫颈癌患者和年龄匹配的对照的相同数量)。在肿瘤患者和对照者的血清中发现了识别不同E6肽的相似患病率(0.8%至4.3%)。使用包含E7 / 1区的28肽合成肽(命名为pepE701),发现了显着差异:116个肿瘤血清样品中有10个,而116个对照血清样品中有0个显示出特异性反应(P小于0.001)。该观察结果证实了HPV-16 E7融合蛋白的早期结果(I. Jochmus-Kudielka,A.Schneider,R.Braun,R.Kimmig,U.Koldovsky,KE Schneweis,K.Seedorf和L.Gissmann,J.Natl (Cancer Inst.81:1698-1704,1989)。在德国测试了从肿瘤患者和对照中收集的188个人血清样品时,发现抗HPV-18 E7抗体的患病率较低(癌症组94阳性中的3个;对照组94个阳性中的0)。当通过Southern杂交在宫颈癌活检中发现的HPV类型与血清反应性进行比较时,证明了抗HPV-18 E7抗体的类型特异性:从HPV-18 DNA阳性获得的8个血清样品中有4个,但在16个血清样品中有0个来自HPV-18 DNA阴性肿瘤患者的HPV-18 E7 ELISA反应。此外,HPV-18阳性血清在多肽ELISA中未能与同源HPV-16 E7区反应(M.Müller,H。Gausepohl,G。de Martinoff,R。Frank,R。Brasseur和L. Gissmann ,J.Gen.Virol.71:2709-2717,1990),反之亦然。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号